Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Profile of the Growth Factors and Other Mediators of Angiogenesis in the Ocular Fluids in Proliferative Retinopathies (AMD and PDR) Before and After the Intravitreal Administration of Bevacizumab (Avastin) as an Anti-VEGF Blocker

NCT00776763 is registered in ClinicalTrials.gov with Ophthalmological Association Edelweiss as lead sponsor.

NCT NCT00776763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00776763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Profile of the Growth Factors and Other Mediators of Angiogenesis in the Ocular Fluids in Proliferative Retinopathies (AMD and PDR) Before and After the Intravitreal Administration of Bevacizumab (Avastin) as an Anti-VEGF Blocker
Lead sponsor
Ophthalmological Association Edelweiss
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2008
Completion date
December 31, 2010
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age related macular degeneration, proliferative diabetic retinopathy